Pursuant to their previously signed distribution agreement dated September 2022, Cosmos will have exclusive distribution rights for Greece and Cyprus, with the opportunity to distribute the ViraxClear
The study's objectives are to assess the safety and tolerability of Decoy20, to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D), as well as to assess Decoy20 pharmacokinetics (PK),
Bristol-Myers Squibb & Co (NYSE:BMY) has returned the exclusive rights to Dragonfly Therapeutics‘ IL-12 oncology candidate. In 2020, BMS handed out $475 million in…
The FDA has accepted for review a marketing application seeking approval for Sage Therapeutics Inc (NASDAQ:SAGE) and Biogen Inc’s (NASDAQ:BIIB) zuranolone for major depressive…
HCR will assume substantially all post-closing liabilities, and RedHill will retain substantially all pre-closing liabilities relating to Movantik (Naloxegol). HCR will retain security interests in certain RedHill assets